Nadia Agopyan - Marker Therapeutics Senior Affairs
| MRKR Stock | USD 1.25 0.05 3.85% |
Executive
Nadia Agopyan is Senior Affairs of Marker Therapeutics
| Address | 9350 Kirby Drive, Houston, TX, United States, 77054 |
| Phone | 713 400 6400 |
| Web | https://markertherapeutics.com |
Nadia Agopyan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nadia Agopyan against Marker Therapeutics stock is an integral part of due diligence when investing in Marker Therapeutics. Nadia Agopyan insider activity provides valuable insight into whether Marker Therapeutics is net buyers or sellers over its current business cycle. Note, Marker Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Marker Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nadia Agopyan over two months ago Acquisition by Nadia Agopyan of 40000 shares of Marker Therapeutics at 3.29 subject to Rule 16b-3 |
Marker Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4192) % which means that it has lost $0.4192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7976) %, meaning that it created substantial loss on money invested by shareholders. Marker Therapeutics' management efficiency ratios could be used to measure how well Marker Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to -0.77. In addition to that, Return On Capital Employed is likely to grow to -1.13. At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 03/21/2025, Net Tangible Assets is likely to grow to about 53.1 M, while Non Current Assets Total are likely to drop 0.00.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Dhan Chand | Agenus Inc | N/A | |
| MS MBA | Alector | 50 | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| Caroline MD | Ikena Oncology | 53 | |
| Alfred Dadson | Agenus Inc | N/A | |
| Robert Strasser | RenovoRx | N/A | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Justin CPA | Tempest Therapeutics | 37 | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Leesa Gentry | RenovoRx | 55 | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| David MS | Ikena Oncology | N/A | |
| David Dornan | Aadi Bioscience | 47 | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.42 |
Marker Therapeutics Leadership Team
Elected by the shareholders, the Marker Therapeutics' board of directors comprises two types of representatives: Marker Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Marker. The board's role is to monitor Marker Therapeutics' management team and ensure that shareholders' interests are well served. Marker Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Marker Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gerald Garrett, Senior Operations | ||
| Juan MD, COO, CoFounder | ||
| Peter MBA, CEO Pres | ||
| Dr Sr, Senior Virology | ||
| Nadia Agopyan, Senior Affairs | ||
| MariaBernadette Madel, Director Communications | ||
| Monic MD, Chief Officer | ||
| Michael Loiacono, Treasurer Secretary | ||
| Mary Newman, Head Affairs | ||
| Robert Sr, Director Virology | ||
| Edmund Cheung, Vice Resources | ||
| Elizabeth Donnelly, Director Administration | ||
| Patricia Allison, Head Operations | ||
| Mythili MD, Chief Officer |
Marker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Marker Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (1.25) % | ||||
| Current Valuation | (4.2 M) | ||||
| Shares Outstanding | 10.71 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 41.80 % | ||||
| Number Of Shares Shorted | 149.81 K | ||||
| Price To Earning | (9.39) X |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.